Skip to content

Software for solar installers, genetics laboratories and cancer research.

Zenit is a software company. Its three products are live on the web, and Zenit Labs is preparing the next ones.

Products

Three products, all live on the web: one for solar installers in Mexico and two for genetics and cancer research.

Zenit Master

Software for solar installers in Mexico.

An installer uploads the customer’s CFE electricity bill and gets a quotation sized to it. From there the same platform designs the system on a 3D model of the roof with shading, draws the single-line diagram to NOM‑001, monitors the plant once it is running and assembles the CFE interconnection paperwork, with CFDI 4.0 invoicing built in.

For
Solar integrators and CFE paperwork agents
Monitoring
Growatt, Hoymiles, Huawei, Solis and more
Access
Subscription in pesos, 7-day free trial
Language
Spanish
Visit zenitmaster.com
The zenitmaster.com home page: “Software para instaladores solares en México” over a photograph of solar panels at dusk.

FilBio

Paternity and maternity index calculator from STR profiles.

Type or import the STR profiles of a child, an alleged parent and, when available, the known parent. FilBio returns the index at each marker, the combined index, the probability of parentage and a printable report. It runs entirely in the browser: the genetic profiles never leave the browser they are typed into.

For
Forensic and paternity-testing laboratories
Data
21 bundled population tables: NIST, FBI, Mexico and UK
Method
Mutation model, 5/2N minimum frequency, never prints 100 %
Language
English and Spanish
Open FilBioSource code (MIT)
FilBio with its worked trio example: marker-by-marker paternity indices and a probability of paternity above 99.999999 %.

LB2 Atlas

Candidate cell-free RNA markers for 29 cancer types.

LB2 looks for genes expressed more in a tumor than in its normal tissue and in blood cells, the pattern a tumor-derived transcript needs to stand out in plasma. Each hit is checked against published plasma cfRNA data. The results are candidates for validation in patient plasma, not validated biomarkers.

For
Cancer and liquid-biopsy researchers
Data
9,059 TCGA tumors, 337 GTEx whole-blood samples, 60,498 genes
Statistics
Wilcoxon rank-sum with FDR control, AUC with DeLong intervals
Language
English
Open LB2 Atlas
The LB2 Atlas home page: from 60,498 genes to 1,364 candidates in lung adenocarcinoma, drawn as a selection flow.
Coming soon

Zenit Labs

Zenit Labs is where Zenit builds cutting-edge prototypes, in hardware and software.

To hear when the first ones are ready, write to hector@zenitmaster.com.

Founder

Héctor Sánchez

Founder of Zenit. Molecular geneticist.

He ran a clinical genetics laboratory and published on the pharmacogenetics of diabetes and on mutations in colorectal cancer before founding Zenit.

ChatGPT release, 30 Nov 2022

Career

  • B.Sc. Genomic Biotechnology, Universidad Autónoma de Nuevo León, Mexico, January 2011 to December 2015.
  • Head of the Genetics Laboratory, Vitagénesis, Monterrey, Mexico, February 2016 to August 2020.
  • M.Sc. Molecular Medicine, Charité – Universitätsmedizin Berlin (DAAD scholar), Germany, September 2020 to October 2022.
  • Enersol, Mexico, November 2022 to May 2024.
  • Research and development scientist, Goodgene, Seoul, South Korea, June 2024 to January 2026.

Papers

Zenit

EducationWorkTraining, work, publications and software since 2011. The dashed line marks the public release of ChatGPT.

Research

The founder’s peer-reviewed work from his years in clinical genetics. The four main papers came out between April 2018 and July 2021, more than a year before ChatGPT’s public release on 30 November 2022.

  1. 2018

    6 April

    Frontiers in Pharmacology 9:320

    Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus

    Sanchez-Ibarra HE, Reyes-Cortes LM, Jiang X-L, Luna-Aguirre CM, Aguirre-Trevino D, Morales-Alvarado IA, Leon-Cachon RB, Lavalle-Gonzalez F, Morcos F, Barrera-Saldaña HA

    Study
    495 patients with type 2 diabetes from northeastern Mexico, treated with oral antidiabetic drugs for at least six months, genotyped for 14 polymorphisms chosen from genome-wide association studies. Response was HbA1c at or below 7 %.
    Analysis
    Hardy–Weinberg and minor-allele-frequency filters left 9 variants. Groups were compared with t, Mann–Whitney, ANOVA and Kruskal–Wallis tests, and genotype–response associations with χ² and Fisher tests under four genetic models, with odds ratios, 95 % intervals and Bonferroni correction (SPSS 20). A global model of every clinical and genetic variable was then fitted by direct coupling analysis; its couplings drew a Bayesian network and fed an additive response predictor, scored by leave-one-out cross-validation (mean prediction rate 0.70).
    Finding
    Heterozygous carriers of ABCC8 Ala1369Ser and KCNJ11 Glu23Lys responded better to sulfonylureas, an association that held after Bonferroni correction.
    Role
    First author. Took part in the genotyping (real-time PCR and Sanger sequencing) and co-wrote the manuscript. The models and the computational framework were built by F. Morcos, X.-L. Jiang and R. León-Cachón, as the paper’s author contributions state.

    Read the paperOpen access (CC BY)doi:10.3389/fphar.2018.00320

  2. 2020

    6 July

    PLOS ONE 15(7):e0235490

    KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study

    Sanchez-Ibarra HE, Jiang X, Gallegos-Gonzalez EY, Cavazos-González AC, Chen Y, Morcos F, Barrera-Saldaña HA

    Study
    500 metastatic colorectal tumors sent from hospitals across Mexico between 2015 and 2018, screened for clinically relevant KRAS, NRAS and BRAF mutations by Sanger sequencing and qPCR.
    Analysis
    χ² and t tests related mutation status to histopathology (SPSS 16). t-SNE (scikit-learn) mapped patients by histological grade, tumor site and region of origin, and a two-layer Keras network with entity embeddings learned to predict KRAS status, evaluated by five-fold stratified cross-validation: AUC 0.71 and 74.1 % mean validation accuracy.
    Finding
    52 % of tumors carried a clinically relevant mutation. Tumors of the proximal colon were associated with KRAS (p = 0.041) and BRAF (p = 0.0065) mutations.
    Role
    First author: conceptualization, investigation, methodology, project administration, and review and editing of the manuscript. Formal analysis by X. Jiang, Y. Chen and F. Morcos (University of Texas at Dallas), per the paper’s CRediT statement.

    Read the paperOpen access (CC BY)doi:10.1371/journal.pone.0235490

  3. 2020

    November

    Revista de Investigación Clínica 72(6):337–343

    Complete Screening of Exons 2, 3, and 4 of KRAS and NRAS Genes Reveals a Higher Number of Clinically Relevant Mutations than Food and Drug Administration Quantitative Polymerase Chain Reaction-Based Commercial Kits

    Sánchez-Ibarra HE, Reyes-Cortes LM, López-Tavera E, Luna-Aguirre CM, Barrera-Saldaña HA

    Study
    Tumors from 1,113 patients with metastatic colorectal cancer, Sanger-sequenced across exons 2, 3 and 4 of KRAS, and 83 of them across the same exons of NRAS.
    Analysis
    Mutation frequencies by gene, exon and codon, compared by age and sex. Every variant found was checked against the mutations the FDA-approved qPCR kits (cobas and therascreen) are able to detect, and annotated with its COSMIC record and FATHMM pathogenicity prediction.
    Finding
    33.7 % of tumors carried a KRAS mutation. About 6 % of the RAS-mutated tumors would have been reported as wild type by an FDA-approved qPCR test.
    Role
    First author.

    Read the paperOpen access (CC BY-NC-ND)doi:10.24875/RIC.20000111

  4. 2021

    15 July

    Pharmacology 106(11–12):588–596

    Transporters, TBC1D4, and ARID5B Variants to Explain Glycated Hemoglobin Variability in Patients with Type 2 Diabetes

    Gonzalez-Covarrubias V, Sánchez-Ibarra H, Lozano-Gonzalez K, Villicaña S, Texis T, Rodríguez-Dorantes M, Cortés-Ramírez S, Lavalle-Gonzalez F, Soberón X, Barrera-Saldaña H

    Study
    100 patients with type 2 diabetes treated with metformin, genotyped genome-wide on the Illumina Global Screening Array.
    Analysis
    Variant association with HbA1c in PLINK; association and prediction models in R with ten-fold cross-validation.
    Finding
    Variants in SLC47A1, SLC28A1, ABCG2, TBC1D4 and ARID5B explained up to 55 % of the variability in HbA1c.
    Role
    Second author.

    Subscription journaldoi:10.1159/000517462

Also

  • 2020

    Barrera-Saldaña HA, Sanchez-Ibarra HE, Treviño-Saenz DL, Fernández-Garza LE. Pharmacoeconomics of metastatic colorectal cancer treatment with targeted therapies guided by companion molecular diagnostics. Journal of Pharmaceutical Research and Therapeutics 1 (2020): 124.

  • 2023

    Yan S, Schöpe PC, Lewis J, … Sanchez-Ibarra HE, … Kobelt D, Stein U. Discovery of tetrazolo-pyridazine-based small molecules as inhibitors of MACC1-driven cancer metastasis. Biomedicine & Pharmacotherapy 168 (2023): 115698. Read it

    His part dates from a 2021 research internship at the Max Delbrück Center, Berlin.

Career

Héctor Eduardo Sánchez-Ibarra trained in genomic biotechnology at the Universidad Autónoma de Nuevo León and in molecular medicine at Charité – Universitätsmedizin Berlin, where he studied as a DAAD scholar.

From 2016 to 2020 he headed the genetics laboratory of Vitagénesis in Monterrey. Its KRAS, NRAS, BRAF and EGFR mutation tests passed the external quality assessments of CAP, EMQN and UK NEQAS with perfect scores from 2016 to 2018, the laboratory obtained its ISO 15189:2012 certification, and he wrote three grants approved by CONACYT, among them the validation of liquid biopsy for lung cancer.

Recognition
Leaders in Innovation Fellowship, Royal Academy of Engineering (UK), 2019
Finalist, TECNOS 4.0 State Award, 2019
Skills
R, Python, MATLAB and Bash. Real-time PCR, Sanger and next-generation sequencing, fragment analysis, cell culture, immunohistochemistry and immunofluorescence.
Languages
Spanish (native), English (C2), German (B2).

  1. 2024–2026

    Research and development scientist

    Goodgene, Seoul

    • qPCR kits for companion diagnostics and liquid biopsy, and a targeted oncology NGS panel.
    • An R program that reads high-resolution melting curves to detect KRAS and EGFR mutations, an NGS variant-calling pipeline, and a Python script that designs primers for custom panels.

  2. 2022–2024

    Enersol

    Mexico

  3. 2020–2022

    M.Sc. Molecular Medicine, DAAD scholar

    Charité – Universitätsmedizin Berlin

    • Time-series and image analysis in R, Python and MATLAB on how the circadian clock controls proliferation (Systems Oncology, Charité Comprehensive Cancer Center, 2021).
    • MACC1 transcriptional inhibitors in several tumor types (Max Delbrück Center, 2021).
    • Thesis on structural proteins of the endothelial glycocalyx, with script-based image analysis in R and Python (Center for Cardiology Research).

  4. 2016–2020

    Head of the Genetics Laboratory

    Vitagénesis, Monterrey

    • Sanger sequencing, real-time PCR, fragment analysis and immunohistochemistry, validated and run under ISO 15189:2012.
    • A qRT-PCR SARS-CoV-2 test service validated by Mexico’s National Institute of Respiratory Diseases.
    • Collaborations with Amgen, Merck and AstraZeneca.

  5. 2011–2015

    B.Sc. Genomic Biotechnology

    Universidad Autónoma de Nuevo León

Contact

hector@zenitmaster.com

Code, including FilBio’s, is on GitHub.